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Abstract 
Background: Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, the most common genetic enzymopathy 
worldwide, is associated with an acute haemolytic anaemia in individuals exposed to primaquine. The present study 
aimed to determine G6PD deficiency among Yemeni children in malaria‑endemic areas as well as to assess the perfor‑
mance of the CareStart™ G6PD rapid diagnostic test (RDT) for its detection.
Methods: A cross‑sectional study recruiting 400 children from two rural districts in Hodeidah governorate was con‑
ducted. Socio‑demographic data and blood samples were collected and G6PD deficiency was qualitatively detected 
in fresh blood in the field using the CareStart™ G6PD RDT, while the enzymatic assay was used to quantitatively meas‑
ure enzyme activity. Performance of the CareStart™ G6PD RDT was assessed by calculating its sensitivity, specificity, 
negative predictive value (NPV), and positive predictive value (PPV) against the reference enzymatic assay.
Results: The ranges of enzyme activity were 0.14–18.45 and 0.21–15.94 units/g haemoglobin (U/gHb) for males and 
females, respectively. However, adjusted male median G6PD activity was 5.0 U/gHb. Considering the adjusted male 
median as representing 100 % normal enzyme activity, the prevalence rates of G6PD deficiency were 12.0 and 2.3 % 
at the cut‑off activities of ≤60 and ≤10 %, respectively. Multivariable analysis showed that gender, district of resi‑
dence and consanguinity between parents were independent risk factors for G6PD deficiency at the cut‑off activity 
of ≤30 % of normal. The CareStart™ G6PD RDT showed 100 % sensitivity and NPV for detecting G6PD deficiency at 
the cut‑off activities of ≤10 and ≤20 % of normal activity compared to the reference enzymatic method. However, it 
showed specificity levels of 90.0 and 95.4 % as well as positive/deficient predictive values (PPVs) of 18.0 and 66.0 % at 
the cut‑off activities of ≤10 and ≤20 %, respectively, compared to the reference method.
Conclusions: G6PD deficiency with enzyme activity of ≤60 % of normal is prevalent among 12.0 % of children resid‑
ing in malaria‑endemic areas of Hodeidah governorate, with 2.3 % having severe G6PD deficiency. Gender, district 
of residence and consanguinity between parents are significant independent predictors of G6PD deficiency at the 
cut‑off activity of ≤30 % of normal among children in malaria‑endemic areas of Hodeidah. The CareStart™ G6PD 
RDT proved reliable as a point‑of‑care test to screen for severely G6PD‑deficient patients, with 100 % sensitivity and 
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Background
Malaria elimination from low and moderate endemic 
countries mainly depends on vector control and prompt 
diagnosis and treatment of infected patients [1]. With 
absence of clinically proven vaccines to block malaria 
transmission to humans [2, 3], there is an increasing 
interest in blocking malaria transmission to mosqui-
toes through the strategic use of gametocytocidal anti-
malarial drugs [4]. Although artemisinin derivatives are 
effective in treating uncomplicated symptomatic falci-
parum malaria and reducing disease transmission by 
targeting young gametocytes of Plasmodium falcipa-
rum [5–8], they show little or no activity against P. fal-
ciparum mature gametocytes [9]. Therefore, the effect 
of artemisinin-based combination therapy (ACT) on the 
transmission of P. falciparum is only moderate based on 
field data [10]. The 8-aminoquinoline, primaquine is the 
only drug commonly used to kill mature P. falciparum 
gametocytes and to clear sub-microscopic gametocytae-
mia after treatment with other anti-malarial drugs [11, 
12]. Despite being recommended by the World Health 
Organization (WHO) for blocking P. falciparum trans-
mission and for preventing Plasmodium vivax relapses, 
primaquine has not been used widely in malaria-endemic 
areas due to concerns about causing acute haemolytic 
anaemia in patients with glucose-6-phosphate dehydro-
genase (G6PD) deficiency [13].
G6PD deficiency is an X-linked recessive hereditary 
enzymopathy affecting millions of people worldwide and 
is more common in malaria-endemic countries [13–15]. 
Haemolysis as a result of G6PD deficiency most com-
monly affects haemizygous males compared to homozy-
gous females, while it depends on the balance between 
the mixed G6PD-normal and -deficient populations of 
red cells in heterozygous females [16]. Several methods 
have been developed for the detection of G6PD defi-
ciency, including the qualitative fluorescent spot test 
(FST), brilliant cresyl blue dye test and the quantitative 
enzymatic assays [14]. Although the International Com-
mittee for Standardization in Haematology (ICSH) rec-
ommends the FST for determining G6PD deficiency [17], 
the quantitative G6PD enzymatic assay remains the ref-
erence method [18–20]. With the current trend of devel-
oping point-of-care diagnostics, rapid diagnostic tests 
(RDTs) have been developed and evaluated for screening 
of G6PD deficiency in the field [21–23].
In Yemen, malaria is a major public health problem, 
with more than 40  % of the population being at high 
risk and more than 100,000 microscopy- and RDT-con-
firmed cases being reported in 2013 [24]. Although real 
estimates of malaria prevalence in the study area are 
not available, partly because of the current social unrest 
in the country, Al-Mekhlafi et al. [25] reported a preva-
lence rate of 15.3 % of falciparum malaria among febrile 
patients in Hodeidah in 2009. However, the situation 
might be even worse if asymptomatic and sub-micro-
scopic infections were considered.
Recently, a G6PD deficiency prevalence rate of 7.1  % 
(36/508) has been reported among male blood donors 
in Sana’a city [26]. However, the prevalence of G6PD 
deficiency in malaria-endemic areas in Yemen remains 
unclear. The national malaria drug policy in Yemen 
adopts primaquine in combination with chloroquine 
for treating vivax malaria and recommends a 14-day 
primaquine dosage for its radical cure [27]. Moreover, 
primaquine-based transmission-blocking strategies for 
paving the way for elimination of falciparum malaria are 
yet to be adopted in the country [28]. Therefore, there is 
a need to include primaquine in the anti-malarial policy 
as a measure to prevent the spread of falciparum malaria 
through targeting mature gametocytes of the parasite as a 
transmission-blocking strategy. However, such a measure 
is limited by the prevalence and severity of G6PD defi-
ciency in malaria-endemic areas, as well as the absence 
of easy-to-use diagnostics for its detection. In pursuit 
of malaria elimination, there is an urgent need to evalu-
ate the performance of RDTs for screening of patients 
with severe G6PD deficiency prior to primaquine use 
in malaria-endemic areas. Although primaquine is rec-
ommended as a single dose of 0.25  mg with ACT to 
patients with falciparum malaria in low transmission 
settings without prior testing, its safety among pregnant 
women and infants less than 6  months is yet to be elu-
cidated [29]. Moreover, data about safety and efficacy of 
the WHO recommendation for the use of a single low-
dose primaquine approach are still limited [30]. For this 
reason, G6PD testing is critically needed before pri-
maquine use in a high-dose regimen for the radical cure 
of vivax malaria as well as before its use as a gametocy-
tocide for falciparum malaria in certain circumstances. 
This is particularly important with the documented evi-
dence of acute haemolysis caused by primaquine among 
NPV, and it can be used for making clinical decisions prior to the administration of primaquine in malaria elimination 
strategies.
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Yemeni patients. In this context, Abdullah [31] reported 
acute intravascular haemolysis in 57 cases after a single 
primaquine administration of 0.75  mg with artesunate, 
which was associated with moderate to severe anaemia, 
hyperbilirubinaemia and death as a result of acute renal 
failure following massive haemolysis.
Therefore, the aim of the present study was to deter-
mine the prevalence and severity of G6PD deficiency 
among children residing in malaria-endemic areas of 
Hodeidah governorate and to evaluate the performance 
of the CareStart™ G6PD RDT for screening of G6PD 
deficiency compared to the reference enzymatic method.
Methods
Study design, setting and ethical clearance
A cross-sectional study design was adopted to determine 
the prevalence and severity of G6PD deficiency among 
children residing in malaria-endemic areas of Hodeidah 
governorate during March 2016. Hodeidah is a coastal 
governorate and port on the Red Sea at the coordinates 
of 14°48′08″N 42°57′04″E (Fig. 1). According to the latest 
population census, its total population is about 2,279,000 
with 1,556,000 being in rural areas and 723,000 in urban 
areas [32]. The study protocol was approved by the Ethics 
Committee of the University of Science and Technology, 
Sana’a. In addition, informed consent was obtained from 
children’s parents or guardians after clearly explaining 
the study objectives.
Sampling strategy
Sample size was calculated according to the WHO prac-
tical manual for the determination of sample size in 
health studies [33], at a confidence level of 95 % and an 
expected G6PD deficiency prevalence of 50  % because 
no data are available from malaria-endemic areas in the 
country. Applying the above criteria, the minimum sam-
ple size required was 384 children. However, 400 children 
were recruited in the present study.
The malaria-endemic districts of Hodeidah were listed, 
and two districts were then randomly selected taking 
into consideration the safe and easy access; namely, Ad 
Durayhimi and Al Marawi’ah districts (Fig.  1). This was 
followed by a two-stage, random sampling of villages and 
households from each district. All children with age from 
2 to 15 years in the selected households were invited to 
voluntarily participate, where the number of children 
recruited from each district was proportional to the total 
population of children in the district.
Blood sampling, data collection and laboratory 
investigations
Three millilitres of venous blood were collected into pre-
labelled EDTA tubes from each participant, kept in an 
icebox and transported on the same day to the laboratory 
of the Military Hospital in Hodeidah city. Data on gen-
der, age, residence, and consanguinity between parents 
were collected using a pre-designed data collection sheet. 
Haemoglobin (Hb) concentration was measured using 
Sysmex KX-21N™ Automated Haematology Analyser 
(Sysmex Corp, Chuo-Ku, Kobe, Japan).
Qualitative screening for G6PD deficiency was per-
formed on fresh venous blood in the field using Car-
eStart™ G6PD RDT (AccessBio, New Jersey, USA) 
according to the manufacturer’s instructions. G6PD 
activity was quantitatively measured within 14 h of blood 
collection using Randox G-6-PDH kits, Cat No PD2616 
(Randox Laboratories Ltd, Antrim, UK) according to the 
manufacturer’s instructions. The technician who carried 
out the quantitative enzymatic assay was blinded to the 
results of the CareStart™ G6PD DT.
Data analysis
Data were entered and analysed using the IBM SPSS Sta-
tistics version 21.0 for Windows (IBM Corp., Armonk, 
NY, USA). Categorical variables were presented as pro-
portions, and differences and associations were tested 
using Pearson’s Chi square test. The odds ratio (OR) and 
its corresponding 95  % confidence interval (CI) were 
reported in the univariate analysis of predictors of G6PD 
deficiency, and multivariable analysis using a  logistic 
regression model was used to determine independent 
predictors of deficiency. The performance of CareStart™ 
G6PD RDT was determined by calculating its sensitiv-
ity, specificity, negative/normal predictive value (NPV), 
and positive/deficient predictive value (PPV) against the 
reference enzymatic assay. The agreement between Car-
eStart™ G6PD RDT and the reference method was tested 
using Cohen’s Kappa coefficient (Kc) [34]. The follow-
ing scale was used to determine the strength of agree-
ment between the two tests: slight: Kc = 0.01–0.20; fair: 
Kc =  0.21–0.40; moderate: Kc =  0.41–0.60; substantial: 
Kc = 0.61–0.8; or almost perfect: Kc = 0.81–1 [35]. The 
significance was considered at p < 0.05.
Results
Characteristics of the study population and determination 
of G6PD‑enzymatic activity
Of the 400 children enrolled in the present study, 55  % 
were males and 45 % were females, with a median age of 
eight years [interquartile range (IQR) 6–11]. The median 
Hb concentration of the children was 11.0  g/dL (IQR 
9.9-11.7). About two-thirds of children were residing in 
Al Marawi’ah district; however, consanguinity between 
children’s parents was higher in Ad Durayhimi district 
than in Al Marawi’ah district, being 46.8 and 35.1  %, 
respectively (Table  1). Table  2 shows the G6PD activity 
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reference values among the studied children as deter-
mined by the quantitative reference enzymatic method. 
The median G6PD activity was equal for both female 
and male children; however, the ranges of enzyme activ-
ity were 0.14–18.45 U/gHb and 0.21–15.94  U/gHb, 
respectively. The adjusted male median G6PD activity 
was 5.0  U/gHb (IQR  =  4.3–5.7  U/gHb), where it was 
used to represent 100 % G6PD activity among the study 
population.
Prevalence and distribution of G6PD deficiency 
among children in Hodeidah governorate
Considering that the adjusted male median G6PD activ-
ity (5.0 U/gHb) represents normal (100 %) enzyme activ-
ity, cut-off values representing ≤10, ≤20, ≤30, ≤40, ≤50 
Fig. 1 Map of Yemen showing Hodeidah governorate and the location of the two study districts
Table 1 Characteristics of the study population
Total number of children enrolled in the present study is 400
Hb haemoglobin, IQR interquartile range
Characteristic
Median age in years (IQR) 8 (6–11)
Gender
 Male n (%) 219 (55)
 Female n (%) 181 (45)
District of residence
 Al Marawi’ah n (%) 259 (65)
 Ad Durayhimi n (%) 141 (35)
Median Hb in g/dL (IQR) 11 (9.9–11.7)
Consanguinity between parents (by district)
 Al Marawi’ah n (%) 91/259 (35.1)
 Ad Durayhimi n (%) 66/141 (46.8)
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and ≤60 % of the normal G6PD activity were determined. 
The prevalence rates of G6PD deficiency ranged from 
2.3 % for those with ≤10 % of normal activity to 12.0 % 
for those with ≤60 % of normal activity (Table 3). Male 
children showed higher G6PD deficiency prevalence 
rates than females at all cut-off values; however, signifi-
cant differences were found at the cut-offs of ≤20–40 % 
of normal activity. In addition, G6PD deficiency was sig-
nificantly more prevalent among children residing in Ad 
Durayhimi compared to those from Al Marawi’ah and 
among children with consanguineous compared to those 
with non-consanguineous parents at all cut-off activities 
(Table 3).
Predictors of G6PD deficiency among children in Hodeidah
Considering that the cut-off of ≤30 % of normal activity as 
the threshold for determining enzyme deficiency before 
primaquine administration, univariate analysis showed that 
gender is significantly associated with G6PD deficiency, 
where male children were at a 2.5-fold higher risk of G6PD 
deficiency than females (OR   =   2.5; 95  % CI 1.18–5.31, 
p = 0.014). In addition, the district of residence (OR  =  2.5; 
95 % CI 1.27–4.89, p = 0.007) and consanguinity between 
the parents (OR  =  2.3; 95 % CI 1.17–4.56, p = 0.013) were 
significant predictors of G6PD deficiency among children 
residing in malaria-endemic areas of Hodeidah. Children 
residing in Ad Durayhimi and whose parents are consan-
guineous were at a higher risk of developing G6PD defi-
ciency compared to those residing in Al Marawi’ah and 
whose parents are non-consanguineous (Table 4). Moreo-
ver, multivariable analysis identified gender, district of resi-
dence and consanguinity between parents as independent 
risk factors for G6PD deficiency at the cut-off of ≤30 % of 
normal activity among children in Hodeidah.
Diagnostic performance of the CareStart™ G6PD RDT 
for detecting G6PD deficiency among children in Hodeidah
At cut-off activities of ≤10 and ≤20 % of normal G6PD 
activity, the CareStart™ G6PD RDT showed 100  % sen-
sitivity (95 % CI 70–100 and 90–100 %, respectively) and 
100  % NPV (95  % CI 99–100  %, each) compared to the 
reference method. However, it had specificity levels of 
90 % (95 % CI 86–92 %) and 95.4 % (95 % CI 93–97 %) as 
well as PPVs of 18 % (95 % CI 10–31 %) and 66 % (95 % 
CI 52–78 %) at the cut-off activities of ≤10 and ≤20 %, 
respectively, compared to the reference method. The Car-
eStart™ G6PD RDT showed a fair degree of agreement 
(89.8 %; Kc = 0.278, p < 0.001) and a substantial degree 
of agreement (95.8  %; Kc  =  0.773, p  <  0.001) with the 
Table 2 G6PD activity among the study population by the 
reference enzymatic method
G6PD glucose‑6‑phosphate dehydrogenase, U/gHb units per gram haemoglobin, 
SD standard deviation, IQR interquartile range
a Reference values were re‑calculated after excluding severe G6PD deficiency, 
and the adjusted male median G6PD activity was used to represent 100 % 
enzyme activity
Reference values 








Range 0.14–18.45 0.21–15.94 1.23–15.94
Median (IQR) 4.7 (4.1–5.5) 4.7 (3.9–5.7) 5.0 (4.3–5.7)
Table 3 Prevalence of G6PD deficiency among children in Hodeidah according to the cut-off activities used to determine 
the enzyme deficiency
G6PD glucose‑6‑phosphate dehydrogenase, CI confidence interval, U/gHb units per gram haemoglobin
** p > 0.05; # p = 0.05; p < 0.05 for all other differences
a Calculated from the median value of 5.0 that is equivalent to 100 % activity
G6PD activity 
cut‑offa













Overall 400 2.3 (1–4) 8.3 (6–11) 9.5 (7–13) 10.3 (8–14) 11.3 (9–15) 12.0 (9–16)
Gender
 Male 219 2.7 (1–6)** 11.4 (8–16) 12.8 (9–18) 13.2 (9–18) 13.7 (10–19)** 14.2 (10–19)**
 Female 181 1.7 (1–5) 4.4 (2–8) 5.5 (3–10) 6.6 (4–11) 8.3 (5–13) 9.4 (6–15)
District of residence
 Al Marawi’ah 259 1.2 (0–3) 5.4 (3–9) 6.6 (4–10) 7.7 (5–12) 8.9 (6–13) 9.3 (6–13)
 Ad Durayhimi 141 4.3 (2–9)# 13.0 (9–20) 14.9 (10–22) 14.9 (10–22) 16.6 (11–22) 17.0 (12–24)
Consanguinity 
between parents
 Yes 157 4.5 (2–9) 13.4 (9–20) 14.0 (9–20) 14.0 (9–20)# 15.9 (11–22) 17.2 (12–24)
 No 243 0.8 (0–3) 4.9 (3–8) 6.6 (4–10) 7.8 (5–12) 8.2 (5–12) 8.6 (6–13)
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reference method in detecting G6PD deficiency at cut-off 
values of ≤10 and ≤20 % of normal activity, respectively 
(Table 5).
On the other hand, the sensitivity of the CareStart™ 
G6PD RDT ranged from 81.3  % (95  % CI 68–90  %) to 
97.4 % (95 % CI 78–100 %) for detecting G6PD deficiency 
at the cut-offs of ≤60 and ≤30 %, respectively, compared 
to the reference method, with comparable specificity 
levels of 96.4–96.9 %. In addition, comparable PPVs and 
NPVs of 74–78 and 97.4–99.7 %, respectively, were found 
for detecting G6PD deficiency using the CareStart™ 
G6PD RDT compared to the reference method at the 
cut-off activities of ≤30–60  % of normal G6PD activ-
ity. The degrees of agreement between the CareStart™ 
G6PD RDT were almost perfect at the cut-off activities 
of ≤30 and ≤40 %, being 96.6 %; Kc = 0.822 and 96.8 %; 
Kc  =  0.839, respectively. However, a substantial degree 
of agreement was found at cut-off activities of ≤50 and 
≤60 %, being 95.8 %; Kc = 0.797 and 95.1 %; Kc = 0.767, 
respectively (Table 5).
Discussion
This is the first study to determine the prevalence of 
G6PD deficiency in malaria-endemic areas of Yemen and 
to evaluate a point-of-care diagnostic tool for its detec-
tion. Because the normal G6PD reference range has not 
been established in the country yet, the adjusted male 
median of G6PD activity (5.0  U/gHb) was considered 
as representing 100  % normal enzyme activity. Given 
that an internationally accepted cut-off for G6PD defi-
ciency is yet to be established, G6PD deficiency cut-off 
thresholds were determined as ranging from ≤10 to 
60 % of the adjusted male median according to the WHO 
Table 4 Predictors of  G6PD deficiency among  children 
in  Hodeidah according to  the cut-off activities used 
to determine the enzyme deficiency
OR odds ratio, CI confidence interval, U/gHb units per gram haemoglobin
a Calculated from the median value of 5.0 that is equivalent to 100 % activity
b All variables were confirmed as independent risk factors using stepwise 
forward logistic regression
Variableb G6PD cut‑off activity of ≤30 % (≤1.5 U/gHb)a
N n (%) OR (95 % CI) p value
Gender
 Male 219 28 (12.8) 2.5 (1.18–5.31) 0.014
 Female 181 10 (5.5) Reference
District of residence
 Ad Durayhimi 141 21 (14.9) 2.5 (1.27–4.89) 0.007
 Al Marawi’ah 259 17 (6.6) Reference
Consanguinity between parents
 Yes 157 22 (14.0) 2.3 (1.17–4.56) 0.013
 No 243 16 (6.6) Reference
Table 5 Performance of  the CareStart™ G6PD RDT for  detecting G6PD deficiency in  comparison to  the reference enzy-
matic method
G6PD glucose‑6‑phosphate dehydrogenase, RDT rapid diagnostic test, EM enzymatic method, CI confidence interval, PPV positive (deficient) predictive value, NPV 
negative (normal) predictive value, U/gHb units per gram haemoglobin, Kc Cohen’s kappa coefficient
a Calculated from the median value of 5.0 that is equivalent to 100 % activity
b % Agreement was calculated by the summation of the number of deficient and normal cases by both RDT and EM divided by the total number of cases and was 
found significant between RDT and EM at all cut‑off activities with p < 0.001















9 33 37 39 39 39
RDT‑deficient vs EM‑
normal (n)
41 17 13 11 11 11
RDT‑normal vs EM‑
normal (n)
350 350 349 348 344 341
RDT‑normal vs EM‑ 
deficient (n)
0 0 1 2 6 9
Sensitivity  % (95 % CI) 100 (70–100) 100 (90–100) 97.4 (87–100) 95.1 (84–99) 86.7 (74–94) 81.3 (68–90)
Specificity  % (95 % CI) 90.0 (86–92) 95.4 (93–97) 96.4 (94–98) 96.9 (94–98) 96.9 (95–98) 96.9 (94–98)
PPV  % (95 % CI) 18.0 (10–31) 66.0 (52–78) 74.0 (60–84) 78.0 (65–87) 78.0 (65–87) 78.0 (65–87)
NPV  % (95 % CI) 100 (99–100) 100 (99–100) 99.7 (98–100) 99.4 (98–100) 98.3 (96–99) 97.4 (95–99)
% Agreement (Kc)b 89.8 (0.278) 95.8 (0.773) 96.6 (0.822) 96.8 (0.839) 95.8 (0.797) 95.1 (0.767)
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classification, with those having ≤10 % of normal enzyme 
activity were considered severely G6PD-deficient [36].
The overall prevalence of G6PD deficiency was 12.0 % 
for children with ≤60  % normal activity (≤3.0  U/gHb). 
However, the prevalence of severe G6PD deficiency 
(≤10 %; ≤0.5 U/gHb) was 2.3 %. This is in contrast to a 
recent finding by Al-Nood et al. [26], who reported that 
all, except for one, of 7.1  % asymptomatic male blood 
donors attending the Blood Bank Department of the 
National Centre of the Public Health Laboratories in 
Sana’a were severely G6PD-deficient, having a G6PD 
activity of <10 % of normal. In addition, the G6PD defi-
ciency prevalence rate is lower than the rates in malaria-
endemic areas in sub-Saharan Africa, where rates as high 
as 30 % have been reported [13].
In general, 10–30  % of normal G6PD activity has 
been predominantly accepted to define severely G6PD-
deficient individuals who should be excluded from pri-
maquine administration [20]. In the present study, at 
the G6PD cut-off-activity of ≤30  % of normal, gender 
of children was a significant independent predictor for 
G6PD deficiency. Male children were at a 2.5-fold higher 
risk than females for developing G6PD deficiency (12.8 
vs 5.5  %) in malaria-endemic areas of Hodeidah. This 
finding is consistent with that recently reported among 
G6PD-deficient Ethiopian malaria suspects [37]. The 
higher frequency of G6PD deficiency among males has 
been reported from different parts of the world and is 
explained by the fact that G6PD deficiency is an X-linked 
hereditary disorder [13, 14, 21, 38–40].
In the present study, district of residence and consan-
guinity between parents were predictors of G6PD defi-
ciency among children residing in malaria-endemic areas 
of Hodeidah. Residing in Ad Durayhimi and having con-
sanguineous parents predict more than a twofold higher 
risk for developing G6PD deficiency among children in 
Hodeidah compared to those living in Al Marawi’ah and 
having non-consanguineous parents. This is supported 
by the higher rate of consanguinity between parents in 
Ad Durayhimi than Al Marawi’ah (46.8 vs 35.1 %). High 
consanguinity rate within communities is a major deter-
minant of the prevalence and burden of X-linked genetic 
disorders, including G6PD deficiency [41, 42]. Like gen-
der of the children, multivariable analysis identifies the 
district of residence and consanguinity as independent 
risk factors for G6PD deficiency at the cut-off of ≤30 % 
of normal enzyme activity among children in Hodeidah. 
Therefore, it is impossible to generalize the G6PD defi-
ciency prevalence rate among children in the present 
study to other malaria-endemic areas in the country. By 
the same token, the Yemeni community is character-
ized by the different traditions related to the preference 
of consanguinity due to its social heterogeneity and 
tribal diversity. It is noteworthy that different prevalence 
and distribution patterns of G6PD variants have been 
reported from different malaria-endemic areas in the 
world [13, 43, 44].
Identifying those at high risk of haemolysis induced 
by primaquine in malaria-endemic areas in limited-
resource countries necessitates the evaluation of suit-
able point-of-care screening tools for G6PD deficiency 
to serve malaria elimination strategies. Of particular 
importance is the screening for G6PD deficiency before 
the use of a high-dose primaquine regimen for the radi-
cal cure of vivax malaria. In addition, screening for the 
enzyme deficiency before low-dose primaquine adminis-
tration as a gametocytocide with ACT in transmission-
blocking strategies is needed for population categories 
with unclear primaquine safety profile such as pregnant 
women and under-six-month infants [29]. Although the 
FST has been recommended by the ICSH as the most 
appropriate method for qualitative screening in the field, 
it requires the use of an ultraviolet lamp, water bath and 
a micropipette for performing the test and a cold chain 
for the preservation of its reagents [17], making it unsuit-
able for rural malaria-endemic areas in resource-limited 
countries. Moreover, its detection threshold has been 
estimated to be around 20 % of normal enzyme activity 
in a large-scale study of over 1.2 million newborns [45].
Alternatively, the findings of the present study show the 
good performance of CareStart™ G6PD RDT for detect-
ing severe G6PD deficiency compared to the reference 
method among children in rural, malaria-endemic areas 
of Hodeidah governorate. The ability of the CareStart™ 
G6PD RDT to detect all severely G6PD-deficient patients 
is strongly supported by the perfect (100  %) sensitivity 
and absolute negative predictability in detecting G6PD 
deficiency and excluding falsely normal G6PD activity in 
individuals testing negative. It is noteworthy that as the 
cut-off activity increases, the sensitivity of the CareStart™ 
G6PD RDT in detecting enzyme deficiency decreases. 
Nevertheless, the CareStart™ G6PD RDT correctly iden-
tifies those with severe deficiency, which makes it reli-
able in identifying patients at particular risk of acute 
haemolysis induced by primaquine. This is a practical 
option because it is difficult to determine the threshold 
of enzymatic activity that should be set for the ideal RDT 
to accurately detect G6PD deficiency [46]. These find-
ings correlate with those concluded by two recent stud-
ies assessing the performance of the CareStart™ G6PD 
RDT in screening G6PD deficiency in Thailand [46] and 
Cambodia [47], where 100  % sensitivity and NPV were 
found for the detection of <30  % G6PD activity against 
the quantitative G6PD assay. Adu-Gyasi et  al. [48] also 
reported 100 % sensitivity of the CareStart™ G6PD RDT 
for detecting G6PD deficiency from capillary blood of 
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Ghanaian participants against Trinity Biotech quanti-
tative G6PD assay; however, a cut-off activity of 75  % 
(equivalent to 4.1  U/gHb) was adopted for evaluation. 
In contrast to the findings of the present study, the Car-
eStart™ G6PD RDT sensitivity of 90.0 and 84.8  % were 
estimated for detecting severely G6PD-deficient Hai-
tian individuals with <10 and <30  % activities of nor-
mal, respectively, against Trinity Biotech quantitative 
assay [49]. Kim et al. [21] also reported lower CareStart™ 
G6PD RDT sensitivity of 68  % but higher specificity of 
100  % for detecting G6PD deficiency in a field evalua-
tion of the test among Cambodians at the lower limit of 
normal activity (a cut-off activity of 3.6  U/gHb) against 
the enzymatic assay. Although the sensitivity of the Care-
Start™ G6PD RDT declines at cut-offs of ≤50 and ≤60 % 
of normal G6PD activity, its high specificity and NPV at 
these cut-offs make it helpful in excluding deficiency in 
those testing negative. Therefore, with the exception of 
those patients testing positive by the RDT, who may need 
careful clinical history taking and/or confirmatory testing 
for G6PD deficiency, primaquine could be given on the 
basis of the RDT result.
Beyond the good performance in detecting severe 
G6PD deficiency, the CareStart™ G6PD RDT maintains 
high sensitivity and specificity of more than 95 % with an 
almost perfect agreement with the reference method at 
cut-offs of ≤30 and ≤40 % of normal G6PD activity. On 
the other hand, the sensitivity of CareStart™ G6PD RDT 
declines with increasing cut-off activities of normal to 
reach as low as about 80 % for detecting ≤60 % enzyme 
activity. However, these cut-off activities are above the 
threshold recommended to consider when administering 
primaquine [20]. In addition to its perfect sensitivity, the 
CareStart™ G6PD RDT also exhibits high specificity of no 
less than 90 % for detecting severe G6PD deficiency. The 
field utility of the CareStart™ G6PD RDT for screening of 
G6PD deficiency is supported by the finding of a previ-
ous study that reported its higher sensitivity compared to 
the FST when using capillary blood [46], making it more 
appropriate for field screening. Although the CareStart™ 
G6PD RDT had been reported to show a high rate of as 
much as 10 % of invalid results when using capillary blood 
[46], none were observed during the present study. It is 
noteworthy, however, that Espino et al. [50] reported that 
the CareStart™ G6PD RDT is more sensitive in detecting 
G6PD deficiency using venous blood compared to capil-
lary blood in a recent study in the Philippines (93.8 vs 
68.8 %, respectively) at a cut-off activity of 30 % of normal. 
Therefore, further studies are needed to explore the best 
performance conditions of the CareStart™ G6PD RDT for 
detecting G6PD deficiency among Yemeni people.
The pivotal role of primaquine in the context of malaria 
elimination lies in its dual ability as a hypnozoitocide to 
radically cure P. vivax malaria and as a gametocytocide 
to eradicate mature P. falciparum gametocytes [51, 52]. 
In addition, primaquine is a major component of arte-
misinin resistance containment programmes to coun-
teract the spread of resistant strains of P. falciparum 
[53]. However, the most life-threatening, primaquine-
induced haemolysis occurs among those with the low-
est residual G6PD activity [54]. Therefore, the ability of 
the CareStart™ G6PD RDT to reliably detect all severely 
G6PD-deficient cases adequately addresses the mini-
mum criteria to be adopted as a screening RDT for severe 
G6PD deficiency among Yemenis residing in malaria-
endemic areas before administering primaquine as part 
of future malaria elimination strategies. Moreover, the 
long-term stability and conserved performance of the 
CareStart™ G6PD RDT at high temperatures [21] makes 
it appropriate for use in malaria-endemic areas in Yemen.
Conclusions
The prevalence of G6PD with ≤60  % of normal activ-
ity among children residing in malaria-endemic areas of 
Hodeidah governorate is 12.0  %, with about 2.3  % hav-
ing severe G6PD deficiency of ≤10  % of normal activ-
ity. Gender, district of residence and consanguinity 
between parents are significant independent predictors 
of G6PD deficiency at the cut-off of ≤60  % of normal 
enzyme activity among children in malaria-endemic 
areas of Hodeidah. Male children who are residing in Ad 
Durayhimi and whose parents are consanguineous are 
a higher risk in developing G6PD deficiency at the cut-
off of ≤30 % of normal enzyme activity. The CareStart™ 
G6PD RDT proved reliable as a point-of-care test to 
screen for severely G6PD-deficient patients and to make 
clinical decisions prior to primaquine administration in 
malaria elimination strategies. It shows 100 % sensitivity 
and NPV for detecting severe G6PD deficiency against 
the reference method. It is recommended that the per-
formance of the CareStart™ G6PD RDT is also evaluated 
for the detection of G6PD deficiency among malaria-
infected patients compared to normal controls. In addi-
tion, genotyping studies for the exploration of G6PD 
variants should be conducted in malaria-endemic areas 
of Yemen.
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